clinical trial · NCT06428409
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 220
Colorectal CancerPancreatic Ductal AdenocarcinomaBiliary Tract CancerSacituzumab tirumotecanFluorouracil (5-FU)Leucovorin (LV) or levoleucovorinRescue medicationSupportive care measuresCisplatinPembrolizumab
brief summary
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
started
Jun 20, 2024
primary completion
Oct 16, 2029
completion
Oct 16, 2029
last updated
Jul 1, 2026
official title
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol